<DOC>
	<DOCNO>NCT01703286</DOCNO>
	<brief_summary>The general aim present study investigate impact 4 week treatment linagliptin ( 5 mg ) endothelial function patient type 2 diabetes mellitus . In current trial effect linagliptin treatment endothelial function compare sulfonylurea glimepiride placebo , test trial ; also case DPP-4 inhibitor . Besides placebo , glimepiride chosen comparator , one compound second use oral antidiabetic drug class .</brief_summary>
	<brief_title>Trial Assess Influence 4 Weeks ' Treatment With Linagliptin Compared Glimepiride Placebo Endothelial Function Patients With Type 2 Diabetes Using FMD ( Flow-Mediated Vasodilation )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : 1 . Type 2 diabetic male female patient accord follow criterion : Based upon complete medical history clinical laboratory test 2 . Age &gt; = 18 Age &lt; = 65 year 3 . Body mass index &gt; = 25 &lt; = 35 kg/m2 4 . HbA1c &lt; = 7.5 % 5 . Treatment metformin ( =1500 mg daily ) &lt; = 3 month 6 . Signed date write informed consent prior admission study accordance GCP local legislation . For female patient childbearing potential : 7 . Use acceptable method contraception ( PearlIndex &lt; 1 ) . Exclusion criterion : 1 . Treatment glucoselowering drug except metformin within prior 3 month . 2 . Any finding medical examination ( include blood pressure , pulse rate electrocardiogram ) deviate normal clinical relevance . 3 . Any evidence clinically relevant acute concomitant disease 4 . History cardiovascular disease ( e.g . coronary artery disease history acute myocard infarction stroke , peripheral vascular disease ) . 5 . History major diabetic complication ( e.g . nephropathy , retinopathy ) 6 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , immunological hormonal disorder ( except : hypertension treat angiotensin receptor blocker angiotensinconvertingenzyme inhibitor , hyperlipidemia statin therapy , thyroid hormone replacement therapy , stable least three month prior screen ) . 7 . Surgery gastrointestinal tract ( except appendectomy ) . 8 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder . 9 . History relevant orthostatic hypotension , faint spell blackout . 10 . Chronic relevant acute infection . 11 . History relevant allergy/hypersensitivity ( include allergy drug excipients ) . 12 . Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial . 13 . Participation another trial investigational drug within one month prior administration trial . 14 . Smoker ( &gt; = 1 cigarette &gt; = 1 cigar &gt; = 1 pipes/day ) . 15 . Alcohol abuse ( 60 g/day ) . 16 . Drug abuse . 17 . Blood donation ( 100 mL within four week prior administration trial ) . 18 . Excessive physical activity ( within one week prior administration trial ) . 19 . Any laboratory value outside reference range clinical relevance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>